Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations
December 12, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology
December 11, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
TeleDaaS™ Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations
November 26, 2023 08:00 ET
|
TeleDaas PLLC
TeleDaaS revolutionizes radiopharmaceutical research by delivering highly-scalable, clinical-grade dosimetry to accelerate cancer treatment breakthroughs.
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
November 09, 2023 21:49 ET
|
Turnstone Biologics Corp.
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
October 30, 2023 06:00 ET
|
Turnstone Biologics Corp.
Internationally recognized cancer immunotherapy thought leader, Dr. Weber, will help guide Turnstone’s continued advancement of its Selected TIL therapies
Neoantigen Cancer Vaccine Market Size is Projected to Reach $1.38 billion by 2030: Straits Research
October 26, 2023 15:00 ET
|
Straits Research
New York, United States, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Neoantigens that arise from cancer-specific mutations are an additional class of antigens that are desirable for therapeutic cancer...
Andira Pharmaceuticals Achieves Remarkable Breast Cancer Tumor Regression with Lead Oncology Candidate XOXO4
October 25, 2023 13:20 ET
|
US Capital Global
San Francisco, California, USA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an affiliate of US Capital Global, recently launched an investment opportunity of up to $5 million...
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 28, 2023 06:00 ET
|
Turnstone Biologics Corp.
Turnstone Biologics to present preclinical data for its Selected TILs at SITC's 38th Annual Meeting.
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update
September 01, 2023 17:57 ET
|
Turnstone Biologics Corp.
Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programsCash position expected to fund operations into second quarter of...
Global CAR T-Cell Therapy Market Size on a Meteoric Rise: Envisioning $2406.39 Million by 2030 with a Striking CAGR of 26.20%
August 23, 2023 04:51 ET
|
Zion Market Research
New York, NY, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “CAR T-Cell Therapy Market By Drug Type (Axicabtagene Ciloleucel, Brexucabtagene...